drugset
drugset / Trial / NCT05059223

A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy

NCT05059223 ↗

Phase 3 Completed 90 enrolled Axsome Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a multi-center, double-blind, placebo-controlled, randomized Phase 3 trial to assess the safety and efficacy of AXS-12 in narcoleptic subjects with cataplexy and excessive daytime sleepiness (EDS).

Timeline

Start
2021-09-15
Primary completion
2024-03-15
Completion
2024-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject AXS-12 Unknown — —

Indications

narcolepsy-cataplexy syndrome